Your SlideShare is downloading. ×
0
Profarma apresentação 1 q10 final
Profarma apresentação 1 q10 final
Profarma apresentação 1 q10 final
Profarma apresentação 1 q10 final
Profarma apresentação 1 q10 final
Profarma apresentação 1 q10 final
Profarma apresentação 1 q10 final
Profarma apresentação 1 q10 final
Profarma apresentação 1 q10 final
Profarma apresentação 1 q10 final
Profarma apresentação 1 q10 final
Profarma apresentação 1 q10 final
Profarma apresentação 1 q10 final
Profarma apresentação 1 q10 final
Profarma apresentação 1 q10 final
Profarma apresentação 1 q10 final
Profarma apresentação 1 q10 final
Profarma apresentação 1 q10 final
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Profarma apresentação 1 q10 final

234

Published on

Published in: Economy & Finance, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
234
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. 1Q10 Earnings Release May, 13th, 2010.
  • 2. 1Q10 Earnings Release Highlights For The Period • Gross revenue reached R$ 766.0 million, showing a 15.8% growth when comparing with the same period of the previous year; • Net profit of the Company increased 15.1% in relation to the same period of the previous year, reaching R$ 7.8 million, representing a net margin of 1.2%; • A 7.8% reduction of the operating expenses, reaching 7.5% of the net operating revenue, representing a reduction of 0.7 percentage point in relation with the same period of the previous year; • Improvement of the service level, reaching 92.3%, an increase of 1.6 percentage point in relation to the same period of the previous year when we reached 90.7%; • Increase of the annual price occurred on March 31st, 2010 was of 4.5% in line with inflation accumulated in the past 12 months, being the second largest increase in the last four years.
  • 3. 1Q10 Earnings Release Gross Revenues Evolution (R$ million) 807.4 766.0 661.8 1Q09 4Q09 1Q10 3
  • 4. 1Q10 Earnings Release Gross Revenues Breakdown (R$ Million) 1Q10 1Q09 Chg. % 4Q09 Chg. % Branded 511.7 453.9 12.7% 546.3 -6.3% Generic 51.6 29.5 74.6% 50.8 1.6% OTC 148.4 129.3 14.7% 157.1 -5.5% Health and Beauty Products 26.8 23.2 15.4% 26.2 2.0% Hospitals and Vaccines 27.6 25.8 7.0% 27.1 1.9% Total 766.0 661.8 15.8% 807.4 -5.1% 4
  • 5. 1Q10 Earnings Release Market Share Evolution (%) 11.7 11.6* 11.5 10.9* 10.9* 9.6 9.6 9.9 2005 2006 2007 2008 2009 1Q09 4Q09 1Q10 *Excluding the similar’s effect Source: IMS 5
  • 6. 1Q10 Earnings Release Gross Profit and Revenues from Services to Suppliers (R$ million and as % Net Revenues) 11.2% 11.0% 10.4% 18.6 5.3 20.0 57.8 57.1 46.5 1Q09 4Q09 1Q10 Gross Profit Revenues from Services to Suppliers Gross Profit Margin (%) 6
  • 7. 1Q10 Earnings Release Operating Expenses (R$ million and as % Net Revenues ) 8.2% 7.4% 7.5% 50.6 48.1 45.9 1Q09 4Q09 1Q10 7
  • 8. 1Q10 Earnings Release Net Financial Expenses (R$ million and as % Net Revenues) 1.4% 0.8% 0.8% 7.8 5.3 5.4 1Q09 4Q09 1Q10 8
  • 9. 1Q10 Earnings Release Net Profit (R$ million and as % Net Revenues) 2.2% 1.2% 1.2% 15.4 7.8 6.7 1Q09 4Q09 1Q10 9
  • 10. 1Q10 Earnings Release Ebitda and Ebitda Margin (R$ million and as % Net Revenues) 4.1% 3.0% 2,8% 28.0 17.9 17.1 1Q09 4Q09 1Q10 10
  • 11. 1Q10 Earnings Release CASH FLOW (R$ Million) 1Q10 1Q09 Chg. % 4Q09 Chg. % Cash Flow Generated / (Used) in Operating Activities (43.9) 36.6 - (19.2) -128.6% Internal Cash Generation 14.5 11.4 27.0% 17.9 -19.1% Operating Assets Variation (58.4) 25.2 - (37.1) -57.3% Trade Accounts Receivable (1.8) 51.5 - (25.1) 92.9% Inventories (24.2) 8.3 - (81.8) 70.5% Suppliers (36.4) (25.3) -44.2% 91.3 - Other Items 4.0 (9.4) - (21.6) - Cash Flow (Used) in Investing Activities (1.5) (3.3) 55.7% (3.6) 59.0% Cash Flow Generated / (Used) by Financing Activities 69.8 (6.2) - (9.9) - Net Increase / (Decrease) in Cash 24.5 27.1 -9.6% (32.6) - 11
  • 12. 1Q10 Earnings Release 3Q06 4Q06 1Q07 2Q07 3Q07 4Q07 1Q08 2Q08 3Q08 4Q08 1Q09 2Q09 3Q09 4Q09 1Q10 Cash Cycle – Days * 49.3 53.4 62.5 69.6 67.8 64.3 68.8 67.2 61.8 65.8 67.9 58.7 51.6 52.7 64.9 Accounts Receivable (1) 45.2 50.0 54.6 53.1 50.9 51.7 50.7 49.2 47.0 45.9 42.4 40.5 38.4 41.1 43.4 Inventories (2) 33.1 44.7 43.4 47.2 41.3 48.6 47.9 45.7 42.5 49.9 54.0 46.5 38.5 49.6 56.2 Accounts Payable (3) 29.0 41.3 35.6 30.7 24.5 36.0 29.8 27.7 27.7 29.9 28.5 28.4 25.3 38.0 34.7 * Average (1) Average of Gross Revenues in the Quarter (2) Average of COGS in the Quarter (3) Average of COGS in the Quarter 12
  • 13. 1Q10 Earnings Release Indebtedness: Net Debt and Net Debt / Ebitda* (R$ million) 1.6x 1.5x 1.1x 167.3 128.0 118.1 1Q09 4Q09 1Q10 * Ebitda = Accumulated last 12 months 13
  • 14. 1Q10 Earnings Release Capex (R$ million and as % Net Revenues) 0.6% 0.5% 0.2% 3.7 3.3 1.5 1Q09 4Q09 1Q10 14
  • 15. 1Q10 Earnings Release Operating Indicators Service Level Logistics E.P.M. (units served / units requested) (Errors per Million) 210.0 93.0% 92.3% 130.0 95.0 90.7% 1Q09 4Q09 1Q10 1Q09 4Q09 1Q10 15
  • 16. 1Q10 Earnings Release Profarma vs Ibovespa 1Q10 140 120 112 103 100 80 60 12/30/09 01/09/10 01/19/10 01/29/10 02/08/10 02/18/10 02/28/10 03/10/10 03/20/10 03/30/10 Ibovespa Profarma 16
  • 17. 1Q10 Earnings Release Analyst Coverage Firm Analyst Javier Martinez de Olcoz Cerdan Morgan Stanley Phone: (1 212) 761-4542 E-mail: javier.martinez.olcoz@morganstanley.com Alexandre Pizano Merrill Lynch Phone: (55 11) 2188-4024 E-mail: alexandre_pizano@ml.com Marcel Moraes Credit Suisse Phone: (55 11) 3841-6302 E-mail: marcel.moraes@credit-suisse.com Juliana Rozenbaum - Marcio Osako Itaú BBA Phone: (55 11) 3073-3035 / (55 11) 3073-3040 E-mail: juliana.rozenbaum@itausecurities.com E-mail: marcio.osako@itau.com.br Iago Whately Banco Fator Phone: (55 11) 3049-9480 E-mail: iwhately@bancofator.com.br 17
  • 18. IR Contacts Max Fischer CFO and IR Director Beatriz Diez IR Manager Telephone,: 55 (21) 4009 0276 E-mail: ri@profarma.com.br www.profarma.com.br/ir

×